All antipsychotics are equal, but some are more equal than others

Journal of Clinical Psychiatry

Volumn 70, Issue 3, 2009, Pages 429-430

  Volavka, Jan ^a   Citrome, Leslie ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

DRUG EFFICACY; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; SHORT SURVEY; ARTICLE; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; COMPARATIVE STUDY; EXTRAPYRAMIDAL SYNDROME; META ANALYSIS; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; COGNITION DISORDERS; HUMANS; META-ANALYSIS AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 64149130932     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09ac05081     Document Type: Short Survey

References (20)

1. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835 (Pubitemid 24986639)
2. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465 (Pubitemid 27147597)
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223 (Pubitemid 41345943)
4. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-1087 (Pubitemid 44498387)
5. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-163
6. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41
7. Citrome L. Compelling or irrelevant? using number needed to treat can help decide. Acta Psychiatr Scand 2008;117:412-419
8. Pani L, Villagran JM, Kontaxakis VP, et al. Practical issues with amisulpride in the management of patients with schizophrenia. Clin Drug Invest 2008;28:465-477
9. Moller HJ. Do effectiveness ("real world") studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci 2008;258(5):257-270
10. Rosenheck RA, Leslie DL, Doshi JA. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making. Psychiatr Serv 2008;59:515-520
11. Tiihonen J, Walhbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333:224-227 (Pubitemid 44406713)
12. Citrome L. Interpreting and applying the CATIE results: with CATIE, context is key, when sorting out phases 1, 1A, 1B, 2E, and 2T. Psychiatry (Edgemont) 2007;4(October):23-29
13. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163:2090-2095 (Pubitemid 46114228)
14. Weiss EM, Bilder RM, Fleischhacker WW. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl) 2002;162:11-17 (Pubitemid 34639550)
15. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028 (Pubitemid 34586949)
16. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64:633-647 (Pubitemid 46878665)
17. Wittorf A, Sickinger S, Wiedemann G, et al. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. Arch Clin Neuropsychol 2008;23(3):271-282
18. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54(9):327-330
19. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-719 (Pubitemid 29266640)
20. Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-1254 (Pubitemid 27369176)